Apalutamide (Erleada™) Extended Metastasis-Free Survival in Resistant Prostate Cancer

MedicalResearch.com Interview with:

Dr. Fred Saad, MD FRCS Full Professor and Chief of Urologic Oncology, CHUM; Medical Director of Interdisciplinary Urologic Oncology Group, CHUM; Department of Surgery/Faculty of Medicine; Institut du cancer de Montréal/CRCHUM

Dr. Saad

Dr. Fred Saad, MD FRCS
Full Professor and Chief of Urologic Oncology, CHUM;
Medical Director of Interdisciplinary Urologic Oncology Group, CHUM;
Department of Surgery/Faculty of Medicine;
Institut du cancer de Montréal/CRCHUM

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: The SPARTAN study was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study that evaluated ERLEADA (apalutamide), a next-generation androgen signaling inhibitor, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who had a rapidly rising PSA (PSA doubling time ≤10 months). The post-hoc analysis presented at the American Urological Association (AUA) 2018 annual meeting showed in patients who received the treatment apalutamide while receiving continuous androgen deprivation therapy (ADT) significantly decreased the risk of PSA progression by 94 percent compared with the placebo group.

MedicalResearch.com: What should readers take away from your report?

Response: These results demonstrated that for patients who are at risk for metastases, apalutamide resulted in a longer time to progression/ appearance of metastases during treatment for non-metastatic CRPC and resulted in substantial and rapid declines in PSA. These data allow clinicians who are taking care of these patients to counsel their patients about what their PSA kinetics levels mean, and potentially adjust therapy accordingly. 

MedicalResearch.com: What recommendations do you have for future research as a result of this work? 

Response: The results from SPARTAN have shown the potential of apalutamide to extend MFS for patients in this disease stage and this has great implications in changing clinical practice. It will also be necessary to study the best treatment approach when patients eventually progress on this type of effective therapy.  

Citation:

Prostate-Specific Antigen (PSA) Outcomes in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Treated With Apalutamide (APA): Results From Phase 3 SPARTAN Study

April 2018
Volume 199, Issue 4, Supplement, Page e232
https://www.jurology.com/article/S0022-5347(18)39931-2/fulltext 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.